top of page

About Us

We are not a supplement brand. We are the science behind one.

Polymor Biotech is a pharmaceutical-grade formulation company specializing in the next generation of PDRN polynucleotide oral delivery technology. We bridge the gap between abstract molecular science and high-performance consumer health products.

As a non-competitive IP partner, we do not market our own retail brands. Instead, we provide the underlying pharmaceutical architecture that enables our partners to claim market leadership through superior bioavailability and clinical validation.

How We Work

We operate as an extension of your R&D department. Our process begins with the science. We identify mechanisms with deep clinical precedent, develop and validate the oral delivery system, and file patent protection — before any licensing conversation begins. You do not brief us on ingredients. You receive a complete, validated, patent-protected complex ready to bring to market under your brand. This ensures that sensitive compounds survive the acidic environment of the stomach, reaching their optimal absorption site intact and fully potent.

What We Build On

Pharmaceutical-grade sourcing

We utilize only high-purity, traceable precursors from vetted global API manufacturers, ensuring that every raw material meets monograph standards for purity and stability before processing.

Enteric delivery architecture

Our proprietary pH-responsive polymer coatings are designed for site-specific release, protecting bioactive molecules from gastric acidity while optimizing absorption in the proximal small intestine.

Patent-first development

Every formulation we develop is built around novel, protectable IP. We focus on non-obvious delivery improvements that provide our partners with a multi-year competitive advantage.

Validated before licensed

No complex is offered for licensing without rigorous dissolution testing, conducted through a certified US laboratory partner. Dissolution data and manufacturing documentation are provided to qualified partners.

Who We Work With

Medical aesthetics

We partner with aesthetic pharmacos to convert systemic dermal treatments into high-bioavailability oral formats, reducing the need for invasive procedures while maintaining professional-grade results across the skin barrier.

Clinical nutrition

For companies targeting medical-grade nutrition, our formulations solve the challenge of nutrient degradation in the gut, ensuring that specific micronutrients and metabolites reach the bloodstream in therapeutic concentrations.

Consumer wellness

We license our delivery IP to premier wellness brands looking to move beyond standard supplements. By integrating our pharmaceutical technology, these brands can prove superior efficacy and claim scientific leadership in the market.

Our Standards

01

Clinical Fidelity

We do not compromise on the pharmaceutical integrity of our formulations. Every project is approached with the same scientific rigor used in drug development, regardless of whether the end product is a nutraceutical or therapeutic.

02

Transparency of Bioavailability

We provide licensing partners with dissolution testing data, formulation documentation, and manufacturing guidance. Everything needed to progress from dossier to GMP production. Additional clinical data will be made available to partners as development milestones are reached.

03

Intellectual Stewardship

Our primary commitment is to the protection and growth of our partners' market position. We act as long-term IP stewards. Each complex in the Polymor pipeline is developed to a standard that supports commercial launch from day one. License agreements include the option to incorporate future Polymor IP improvements as the science advances.

Polymor Biotech sits at the intersection of medical science and biotechnology. As a pioneer in enteric delivery and oral bioavailability, we provide the technical infrastructure necessary for pharmaceutical companies and wellness brands to deliver clinical efficacy through non-invasive systems. We are the architects of the next generation of oral delivery.

bottom of page